Much attention has been paid recently to RNA interference (RNAi), a technique in which exogenous, double-stranded RNAs (dsRNAs) are introduced into a cell to specifically destroy a particular mRNA, thereby diminishing or abolishing gene expression.1 The technique has proven effective in Drosophila, Caenorhabditis elegans, plants, and recently, in mammalian cell cultures.2
To make the technique work in cultured mammalian cells, researchers must deliver small interfering RNAs (siRNAs), which are dsRNAs of 21-25 nucleotides, to the cell. They can use a wide range of standard transfection reagents optimized for DNA and RNA, but according to Kathy Latham, RNAi product manager for Austin, Texas-based Ambion, reagents designed to deliver mRNAs, for instance, are not adept at transfecting smaller siRNAs. "It's like the difference between plasmids and oligos," she says, referring to manufacturers' offering different formulations to transfect plasmid DNA and shorter oligonucleotides.
As a result, both Ambion and Madison, Wis.-based Novagen have ...